EASi-PROTKT
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, arterial hypertension and established cardiovascular disease
- Stadium
- inclusie
- Middel
- Vicadrostat + Enpagliflozin
- Populatie
- ASCVD
- Fase
- III
- First Patient In
- 1 januari 2026
- Last Patient In
- 31 december 2026
- Last Patient Last Visit
- 12 oktober 2029
Inclusieperiode, nog 349 dagen over
National Lead
prof. dr. F.M.A.C. Martens
Cardioloog
Studiedirecteur
